Welcome to our dedicated page for Universe Pharmaceuticals SEC filings (Ticker: UPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings and related disclosures for Universe Pharmaceuticals Inc. (UPC), a pharmaceutical producer and distributor in China focused on traditional Chinese medicine derivatives and third-party healthcare products. The company files reports as a foreign private issuer, and these documents offer detailed insight into its operations, financial condition, and corporate actions.
Key filings for Universe Pharmaceuticals include annual reports on Form 20-F, which present audited financial statements, risk factors, business descriptions, and information on traditional Chinese medicine derivatives (TCMD) products and third-party products. Interim financial information and significant corporate events are furnished on Form 6-K, such as financial highlights for the six months ended March 31, 2025, including revenue breakdowns between TCMD and third-party products, gross margin data, operating expenses, and net income or loss.
Universe Pharmaceuticals also uses Form 6-K to report corporate governance and capital structure matters. Examples include notices and proxy statements for annual general meetings of shareholders, results of shareholder votes, and details of capital reorganizations. One 6-K describes a capital reorganization involving a reduction in par value of issued ordinary shares, subdivision and alteration of authorized share capital, and the creation of new share classes with specified voting rights and conversion features, along with the redesignation of existing issued shares into those new classes.
Filings further document equity financing activities, such as registered direct offerings made under an effective shelf registration statement on Form F-3, as well as information about share consolidations (reverse share splits) and changes in authorized share capital. Listing-related developments, including Nasdaq notifications about minimum bid price, market value of publicly held shares, and delayed Form 20-F filings, may appear in 6-K reports as well.
On this page, AI-powered tools can help summarize lengthy filings, highlight key figures and trends, and point out important sections on topics such as revenue composition, operating performance, capital structure, and shareholder approvals. Users can review Forms 20-F and 6-K, along with other available documents, to understand Universe Pharmaceuticals’ regulatory disclosures and historical reporting.
Universe Pharmaceuticals INC adopted a new 2026 Equity Incentive Plan on April 14, 2026 to attract and retain employees, directors, and consultants and align their interests with shareholders.
The plan initially reserves up to 84,500 ordinary shares for awards and allows options, share appreciation rights, restricted shares, restricted share units, performance units, performance shares, and other share-based awards. From the first trading day in January 2027, the share pool may automatically increase each year by up to 10% of total ordinary shares issued and outstanding, subject to the Company’s authorized share capital and any lower amount set by the board. No director or officer can receive awards that would lift their holding above 75% of total voting power, and option terms may not exceed 10 years from the grant date.
Universe Pharmaceuticals INC director files initial ownership report. Zheng Ding, a director of Universe Pharmaceuticals INC, submitted a Form 3, which is an initial statement of beneficial ownership of securities. The data provided shows no reported purchases, sales, or other equity transactions in this filing.
Universe Pharmaceuticals INC director and Chief Executive Officer Lai Gang has filed an initial Form 3 reporting his beneficial ownership in the company. The filing shows indirect ownership of 3,467 Class B ordinary shares, par value US$0.00001 per share, held through Sununion Holding Group Limited, a British Virgin Islands company that is 100% owned and controlled by him.
Universe Pharmaceuticals INC filed an initial insider ownership report for Chief Operating Officer Liu Baochang. This Form 3 identifies Liu as an officer of the company and establishes his status as an insider for future reporting, but it does not list any buy, sell, or other share transactions.
Universe Pharmaceuticals INC director Pang Jiawen has filed an initial statement of beneficial ownership on Form 3. This filing establishes Pang’s status as a director of the company and does not report any stock transactions or holdings at this time.
Universe Pharmaceuticals INC director and Chief Financial Officer Yang Lin (Lydia) filed an initial Form 3 reporting insider status in the company. The filing lists no purchases, sales, gifts, or other equity transactions, and shows no derivative positions in this excerpt.
Universe Pharmaceuticals INC director Yu Yongping has filed an initial insider ownership report on Form 3 for the company’s common equity. The filing lists no insider transactions or option exercises and shows no derivative positions, serving mainly as a baseline disclosure of Yu Yongping’s status as a director.
Universe Pharmaceuticals INC has confirmed that all conditions for its dual-class share structure have been met and that the structure will become effective on the Nasdaq Capital Market on February 13, 2026. From that date, its Class A ordinary shares will continue trading under the symbol “UPC” with the same CUSIP.
The company amended and restated its memorandum and articles of association, changing its authorized share capital to US$20,000 divided into 1,800,000,000 Class A ordinary shares and 200,000,000 Class B ordinary shares, each with a par value of US$0.00001. This formalizes a new capital and voting structure while leaving the trading symbol and market listing unchanged.
Universe Pharmaceuticals INC, a Cayman Islands holding company with operations in China, files its annual report for the year ended September 30, 2025. The company reports revenues declining from $32,308,735 in 2023 to $23,024,458 in 2024 and $17,858,732 in 2025, with net losses of $6,581,024, $8,727,298, and $3,672,055, leading to an accumulated deficit of $13,843,623. As of September 30, 2025, it has 563,338 ordinary shares outstanding and relies heavily on short-term bank financing, with $9,256,919 of debt due within one year and additional capital expenditure commitments for new factories and an office project now delayed to June 30, 2028. The report highlights significant risks from PRC regulation, data and cybersecurity rules, foreign listing oversight, cash-transfer and dividend constraints, as well as potential Nasdaq delisting and HFCAA-related trading risks, while noting that no dividends have been paid and future earnings are expected to be retained.
Universe Pharmaceuticals INC reported that Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz together beneficially own 28,111 ordinary shares, representing 4.9% of the company’s ordinary shares as of the event date. All three reporting persons have no sole voting or dispositive power over these shares, but share voting and dispositive power for the full 28,111 shares. They certify that the securities were acquired and are held on a passive basis, not for the purpose of changing or influencing control of Universe Pharmaceuticals.